Diagnostics require precision and predictive ability to be clinically useful. Integration of multi-
omic with clinical data is crucial to our understanding of disease pathogenesis and …

Clinical genomic testing is becoming routine in prostate cancer, as biomarker‐driven
therapies such as poly‐ADP ribose polymerase (PARP) inhibitors and anti‐PD1 …

Background Refinement of the risk classification for localized prostate cancer is warranted to
aid in clinical decision making. A systematic analysis was undertaken to evaluate the …

The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored
by active surveillance rather than undergoing immediate treatment. However, a subset of …

Purpose The Oncotype DX Genomic Prostate Score (GPS) assay has been validated as a
strong prognostic indicator of adverse pathology, biochemical recurrence, distant metastasis …

Cribriform growth pattern is well-established as an adverse pathologic feature in prostate
cancer. The literature suggests “large” cribriform glands associate with aggressive behavior; …

The validated 17-gene Oncotype DX Genomic Prostate Score®(GPS™) assay risk-stratifies
prostate-cancer patients with localized disease. The assay has primarily been utilized in …

Prostate Cancer Tissue-Based Biomarkers - StatPearls - NCBI Bookshelf US flag An official
website of the United States government Here's how you know NIH NLM Logo Access keys …

Current diagnostic and prognostic tests for prostate cancer require specialised laboratories
and have low specificity for prostate cancer detection. As such, recent advancements in …

Purpose To assess the association of adverse pathology (AP), defined as high-grade (≥
Gleason Grade Group 3) and/or non-organ confined disease, with long-term oncologic …